In chronic granulocytic leukemia (CML), MDSCs and the levels of their immunosuppressive markers IL-10 and ARG1 are elevated, and the tyrosine kinase inhibitor (TKI) imatinib and dasatinib treatments can reduce MDSC levels to within the normal range [111, 112]. This evidence concerns the gene ARG1 and chronic myelogenous leukemia, BCR-ABL1 positive.